News for Cogent Biosciences, Inc. (COGT)

Ӣ Top-line results from SUMMIT trial in NonAdvSM patients expected July 2025 Ӣ APEX trial enrollment in AdvSM patients complete; top-line results expected

Net Loss: Reported a net loss of $67.9 million for Q4 2024, compared to $54.4 million in Q4 2023.Research and Development Expenses: Increased to $62.0 million

On December 31, 2024, Steven Cohen (Trades, Portfolio) executed a significant transaction involving Cogent Biosciences Inc (COGT). This transaction saw a reduct

On February 5, 2025, Paradigm Biocapital Advisors LP (Trades, Portfolio) made a significant move by acquiring an additional 950,162 shares of Cogent Biosciences

On December 31, 2024, FMR LLC (Trades, Portfolio) made a significant move by acquiring an additional 3,360,284 shares of Cogent Biosciences Inc (NASDAQ: COGT) a

Here is how Cogent Biosciences, Inc. (COGT) and Cardiol Therapeutics Inc. (CRDL) have performed compared to their sector so far this year.

**media[536837]**

Bezuclastinib's upcoming data in July 2025 could be a game-changer for COGT, offering a lucrative investment opportunity. See why COGT stock is buy rated.

Ackman’s Pershing Square Moves To Kick Off Universal Music U.S.

Cogent Biosciences (COGT) stock, ModivCare (MODV) stock, and Avadel Pharmaceuticals (AVDL) stock rise after insider purchases. Read more here.

Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today ann

Ӣ Plan to report top-line results from registration-directed SUMMIT trial in NonAdvSM patients in July 2025 Ӣ Plan to report top-line results from

U.S. stock futures were mostly higher this morning, with the Dow futures gaining around 0.1% on Tuesday. Shares of Acelyrin, Inc. SLRN fell sharply in today's ...

Blueprint Medicines generates strong revenue growth from its FDA-approved product AYVAKIT, reporting $92.5 million in Q1'24 net product revenues. Read more here.

Shares of Sony Group Corporation (NYSE: SONY) fell during Wednesday’s session after the company reported third-quarter financial results and revised guidance above estimates and shared plans to list its financial arm in October 2025.

GuruFocus Article or News written by GuruFocus Research and the topic is about:

Small-cap investors took a beating in 2022 as data shows that small-cap stocks are near their all-time lows.

Read Cogent Biosciences (NASDAQ:COGT) and Abliva AB (publ) (OTCMKTS:NEVPF) Head-To-Head Analysis at ETF Daily News

While Most of Wall Street focuses on large and mega cap stocks, as they provide a degree of safety and liquidity, many investors are limited in the amount of shares they can buy. Many of the biggest public companies, especially the technology giants, trade in the low to mid-hundreds all the way up to over […]